

## Corporate Sponsored Presentations

Session Time (PDT)/ Location	Abstract #/Title/Lead Author	Type/Session
<b>Saturday, December 9, 2023</b>		
Saturday, December 9, 2023 5:30-7:30 PM Halls G-H	<b>1440 / SGN-35C</b> SGN-35C: a novel CD30-directed antibody-drug conjugate for the treatment of lymphomas <b>Lead Author: Hamblett</b>	<b>Poster Presentation</b> Session 1
<b>Sunday, December 10, 2023</b>		
Sunday, December 10, 2023 4:45PM Grand Hall B	<b>608 / Brentuximab Vedotin SGN35-027 Part B</b> Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced stage classical Hodgkin lymphoma: Updated efficacy and safety results from the single arm phase 2 study <b>Lead Author: Lee</b>	<b>Oral Presentation</b> Session 624
Sunday, December 10, 2023 5:30PM Grand Hall B	<b>611 / Brentuximab Vedotin SGN35-027 Part C</b> Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) for early-stage classical Hodgkin lymphoma: Updated results reporting progression-free survival in an ongoing phase 2 study (SGN35-027 Part C) <b>Lead Author: Abramson</b>	<b>Oral Presentation</b> Session 624
Sunday, December 10, 2023 6:00-8:00PM Hall G-H	<b>3074 / Brentuximab Vedotin ECHELON-2</b> PET4 response as an independent predictor of outcomes in ECHELON-2 A+CHP vs CHOP in CD30+PTCL: Long-term follow-up <b>Lead Author: Iyer</b>	<b>Poster Presentation</b> Session 2
<b>Monday, December 11, 2023</b>		
Monday, December 11, 2023 6:00-8:00PM Halls G-H	<b>4435 / Brentuximab Vedotin SGN35-015 Part E</b> Brentuximab vedotin in frontline therapy of Hodgkin lymphoma in patients with significant comorbidities ineligible for standard chemotherapy (SGN35-015 Part E) <b>Lead Author: Yasenchak</b>	<b>Poster Presentation</b> Session 3

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

**IST Presentations**

Session Time (PDT)/ Location	Abstract #/Title/Lead Author	Type/Session
<b>Saturday, December 9, 2023</b>		
Saturday, December 9, 2023 2:00PM Grand Hall B	<b>181 / Brentuximab Vedotin SWOG S1826</b> Nivolumab-AVD is better tolerated and improves progression-free survival compared to BV-AVD in older patients (aged ≥60 years) enrolled on SWOG S1826 <a href="#">Lead Author: Rutherford</a>	<b>Oral Presentation</b> Session 624
Saturday, December 9, 2023 5:30-7:30PM Halls G-H	<b>1702 / Brentuximab Vedotin SGN35-IST-042</b> Reduced dose brentuximab vedotin for mycosis fungoides appears to prolong response duration by balancing efficacy and tolerability <a href="#">Lead Author: Munayirji</a>	<b>Poster Presentation</b> Session 1
Saturday, December 9, 2023 5:30-7:30PM Halls G-H	<b>1692 / Brentuximab Vedotin SGN35-IST-044</b> Final results of a multicenter pilot study evaluating brentuximab vedotin with cyclophosphamide, doxorubicin, etoposide, and prednisone (BV-CHEP) for the treatment of aggressive adult T-cell leukemia/lymphoma <a href="#">Lead Author: Dittus</a>	<b>Poster Presentation</b> Session 1
<b>Sunday, December 10, 2023</b>		
Sunday, December 10, 2023 5:15PM Grand Hall B	<b>610 / Brentuximab Vedotin SWOG S1826</b> Progression-Free Survival (PFS) and toxicity with nivolumab-AVD compared to brentuximab vedotin-AVD in pediatric advanced stage (as) classic Hodgkin lymphoma (cHL), results of SWOG S1826 <a href="#">Lead Author: Castellino</a>	<b>Oral Presentation</b> Session 624
Sunday, December 10, 2023 5:45PM Grand Ballroom 2-4	<b>672 / Brentuximab Vedotin AHOD1331</b> Longitudinal differences by treatment arm in health-related quality of life among high-risk pediatric Hodgkin's lymphoma patients treated on the Children's Oncology Group AHOD1331 study <a href="#">Lead Author: Williams</a>	<b>Oral Presentation</b> Session 905
Sunday, December 10, 2023 6:00-8:00PM Halls G-H	<b>3084 / Brentuximab Vedotin AHOD2131</b> AHOD2131: a randomized phase 3 response-adapted trial comparing standard therapy with 2 immune-oncology therapy for children and adults with newly diagnosed stage I and II classic Hodgkin lymphoma [TIP] <a href="#">Lead Author: Henderson</a>	<b>Poster Presentation</b> Session 2
Sunday, December 10, 2023 6:00-8:00PM Halls G-H	<b>3060 / Brentuximab Vedotin SGN35-IST-013</b> Brentuximab vedotin in combination with nivolumab in CD30+ malignancies refractory to brentuximab vedotin <a href="#">Lead Author: Poh</a>	<b>Poster Presentation</b> Session 2
Sunday, December 10, 2023 6:00-8:00PM Halls G-H	<b>3066 / Brentuximab Vedotin Meta-analysis</b> CNS involvement in pediatric Hodgkin lymphoma: a comprehensive retrospective analysis from the SEARCH for CAYAHL group <a href="#">Lead Author: Pabari</a>	<b>Poster Presentation</b> Session 2
<b>Monday, December 11, 2023</b>		
Monday, December 11, 2023 6:00-8:00PM Halls G-H	<b>4383 / Brentuximab Vedotin AHOD 1331</b> Identifying tumor-specific immune response and biomarkers of high-risk Hodgkin lymphoma patients treated with and without brentuximab on Children's Oncology Group trial AHOD1331 <a href="#">Lead Author: Toner</a>	<b>Poster Presentation</b> Session 3
Monday, December 11, 2023 6:00-8:00PM Halls G-H	<b>4382 / Brentuximab Vedotin NCI ECOG ACRIN 4412</b> Immune features associated with response to brentuximab vedotin with ipilimumab and/or nivolumab in Hodgkin lymphoma <a href="#">Lead Author: Gonzalez-Kozlova</a>	<b>Poster Presentation</b> Session 3

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.